期刊
NEUROMODULATION
卷 25, 期 2, 页码 161-170出版社
ELSEVIER
DOI: 10.1111/ner.13483
关键词
Animal studies; biomarker; closed-loop system; deep brain stimulation; depression; neuroscience; psychiatry
资金
- National Institute of Health (NIH) [R01NS112176]
- Grainger Foundation
- NIH [F31NS115202-01A1, R25GM055252-23, TL1TR002380-03, T32GM065841-17]
- Boston Scientific Fellowship Grant
- NHMRC Senior Principal Research Fellowship [1059660, 1156072]
Despite recent advances in depression treatment, many patients still do not respond to serial conventional therapies and are considered treatment resistant. Deep brain stimulation (DBS) has therapeutic potential in this context. This comprehensive review of recent studies of DBS for depression in animal models identifies potential biomarkers for improving therapeutic efficacy and predictability of conventional DBS to aid future development of closed-loop control of DBS system.
Objectives Despite recent advances in depression treatment, many patients still do not respond to serial conventional therapies and are considered treatment resistant. Deep brain stimulation (DBS) has therapeutic potential in this context. This comprehensive review of recent studies of DBS for depression in animal models identifies potential biomarkers for improving therapeutic efficacy and predictability of conventional DBS to aid future development of closed-loop control of DBS system. Materials and Methods A systematic search was performed in Pubmed, EMBASE, and Cochrane Review using relevant keywords. In overall, 56 animal studies satisfied the inclusion criteria. Results Outcomes were divided into biochemical/physiological, electrophysiological, and behavioral categories. Promising biomarkers include biochemical assays (in particular, microdialysis and electrochemical measurements), which provide real-time results in awake animals. Electrophysiological tests, showing changes at both the target site and downstream structures also revealed characteristic changes at several anatomic targets (such as the medial prefrontal cortex and locus coeruleus). However, the substantial range of models and DBS targets limits the ability to draw generalizable conclusions in animal behavioral models. Conclusions Overall, DBS is a promising therapeutic modality for treatment-resistant depression. Different outcomes have been used to assess its efficacy in animal studies. From the review, electrophysiological and biochemical markers appear to offer the greatest potential as biomarkers for depression. However, to develop closed-loop DBS for depression, additional preclinical and clinical studies with a focus on identifying reliable, safe, and effective biomarkers are warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据